PMID- 37152739
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230509
IS  - 1664-302X (Print)
IS  - 1664-302X (Electronic)
IS  - 1664-302X (Linking)
VI  - 14
DP  - 2023
TI  - Effects of the synbiotic composed of mangiferin and Lactobacillus reuteri 1-12 on 
      type 2 diabetes mellitus rats.
PG  - 1158652
LID - 10.3389/fmicb.2023.1158652 [doi]
LID - 1158652
AB  - Many synbiotics are effective for the prevention and treatment of type 2 diabetes 
      mellitus (T2DM). In the treatment of T2DM, synbiotics often regulate the 
      composition of intestinal flora, which autoinducer-2 (AI-2) may play an important 
      role. Whether the changes of intestinal flora are related to AI-2 during 
      synbiotics treatment of T2DM is a topic worth studying. We elucidated the effects 
      of synbiotic composed of mangiferin and Lactobacillus reuteri 1-12 (SML) on T2DM 
      rats. Male Spraque-Dawley rats were injected intraperitoneally with 
      streptozotocin (STZ) and randomly grouped. After that, biochemical parameters, 
      intestinal flora, fecal AI-2, and intestinal colonization of L. reuteri were 
      detected. The results showed that SML had a hypoglycemic effect and mitigated the 
      organ lesions of the liver and pancreas. Also, SML regulated biochemical 
      parameters such as short chain fatty acids (SCFAs), lipopolysaccharides (LPS), 
      intercellular cell adhesion molecule-1 (ICAM-1), and tumor necrosis factor-alpha 
      (TNF-alpha). On the other hand, the proportion of probiotics, such as Lactobacillus 
      acidophilus, L. reuteri, Bifidobacterium pseudolongum, Lactobacillus murinus, and 
      Lactobacillus johnsonii, were elevated by the treatment of SML. In addition, SML 
      promoted the colonization and proliferation of L. reuteri in the gut. Another 
      thing to consider was that AI-2 was positively correlated with the total number 
      of OTUs sequences and SML boosted AI-2 in the gut. Taken together, these results 
      supported that SML may modulate intestinal flora through AI-2 to treat T2DM. This 
      study provided a novel alternative strategy for the treatment of T2DM in future.
CI  - Copyright (c) 2023 Meng, Zhang, Meng, Chen, Yang, Wang, Xie, Li, Gu and Yu.
FAU - Meng, Fanying
AU  - Meng F
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
FAU - Meng, Meng
AU  - Meng M
AD  - State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and 
      Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, 
      China.
FAU - Chen, Qiuding
AU  - Chen Q
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
FAU - Yang, Yaqin
AU  - Yang Y
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
FAU - Wang, Wenbo
AU  - Wang W
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
FAU - Xie, Haina
AU  - Xie H
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
FAU - Li, Xue
AU  - Li X
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
FAU - Gu, Wen
AU  - Gu W
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
FAU - Yu, Jie
AU  - Yu J
AD  - Yunnan Key Laboratory of Southern Medicine Utilization, College of Pharmaceutical 
      Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
LA  - eng
PT  - Journal Article
DEP - 20230420
PL  - Switzerland
TA  - Front Microbiol
JT  - Frontiers in microbiology
JID - 101548977
PMC - PMC10157401
OTO - NOTNLM
OT  - Lactobacillus reuteri 1-12
OT  - autoinducer-2
OT  - intestinal flora
OT  - mangiferin
OT  - quorum sensing
OT  - synbiotic
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/08 06:41
MHDA- 2023/05/08 06:42
PMCR- 2023/04/20
CRDT- 2023/05/08 04:07
PHST- 2023/02/27 00:00 [received]
PHST- 2023/04/03 00:00 [accepted]
PHST- 2023/05/08 06:42 [medline]
PHST- 2023/05/08 06:41 [pubmed]
PHST- 2023/05/08 04:07 [entrez]
PHST- 2023/04/20 00:00 [pmc-release]
AID - 10.3389/fmicb.2023.1158652 [doi]
PST - epublish
SO  - Front Microbiol. 2023 Apr 20;14:1158652. doi: 10.3389/fmicb.2023.1158652. 
      eCollection 2023.